Cynata Therapeutics Ltd - Asset Resilience Ratio
Cynata Therapeutics Ltd (CYP) has an Asset Resilience Ratio of 0.05% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Cynata Therapeutics Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Cynata Therapeutics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CYP total asset value.
Liquid Assets Composition Over Time
This chart breaks down Cynata Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Cynata Therapeutics Ltd (CYP) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.57K | 0.05% |
| Total Liquid Assets | AU$3.57K | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Cynata Therapeutics Ltd maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cynata Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Cynata Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
Annual Asset Resilience Ratio for Cynata Therapeutics Ltd (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Cynata Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.05% | AU$3.57K ≈ $2.53K |
AU$7.20 Million ≈ $5.09 Million |
+0.01pp |
| 2024-06-30 | 0.04% | AU$3.57K ≈ $2.53K |
AU$8.39 Million ≈ $5.94 Million |
-0.09pp |
| 2023-06-30 | 0.13% | AU$25.53K ≈ $18.06K |
AU$18.99 Million ≈ $13.44 Million |
+0.04pp |
| 2022-06-30 | 0.10% | AU$25.53K ≈ $18.06K |
AU$26.55 Million ≈ $18.78 Million |
+0.01pp |
| 2021-06-30 | 0.09% | AU$25.53K ≈ $18.06K |
AU$29.97 Million ≈ $21.21 Million |
+0.06pp |
| 2020-06-30 | 0.02% | AU$3.57K ≈ $2.53K |
AU$17.48 Million ≈ $12.37 Million |
-0.01pp |
| 2019-06-30 | 0.03% | AU$3.57K ≈ $2.53K |
AU$12.25 Million ≈ $8.67 Million |
-- |
About Cynata Therapeutics Ltd
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more